金沙集团1862cc(股份)有限公司-baidu百科

2025-08-26

Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...

查看详情

08-162024

Bio-Thera Solutions and Pharmapark Further Expand Partnership in Russia and other CIS Countries with Addition of BAT2306, a Cosentyx® Biosimilar

GUANGZHOU, China and MOSCOW, Russia --- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stagebiopharmaceutical compan...
07-302024

European Medicines Agency (EMA) Approves Bio-Thera Solutions’ BAT1706 (Avzivi®, bevacizumab), a biosimilar referencing Avastin®

BAT1706 is Bio-Thera Solutions’ second EMAapproved product BAT1706 is Bio-Thera Solutions’ secondproduct receiving marke...
07-252024

Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, a Proposed Biosimilar of Keytruda® (Pembrolizumab)

Guangzhou, China– July 25, 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeve...